Skip to main navigation
Skip to search
Skip to main content
The Hebrew University of Jerusalem Home
Approve / Request updates on publications
Home
Profiles
Research units
Research output
Prizes
Search by expertise, name or affiliation
Autologous transplantation and maintenance therapy in multiple myeloma
A. Palumbo
*
, F. Cavallo
, F. Gay
, F. Di Raimondo
,
D. B. Yehuda
, M. T. Petrucci
, S. Pezzatti
, T. Caravita
, C. Cerrato
, E. Ribakovsky
, M. Genuardi
, A. Cafro
, M. Marcatti
, L. Catalano
, M. Offidani
, A. M. Carella
, E. Zamagni
, F. Patriarca
, P. Musto
, A. Evangelista
G. Ciccone, P. Omedé, C. Crippa, P. Corradini, A. Nagler, M. Boccadoro, M. Cavo
Show 7 others
Show less
*
Corresponding author for this work
Research output
:
Contribution to journal
›
Article
›
peer-review
694
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Autologous transplantation and maintenance therapy in multiple myeloma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Multiple Myeloma
100%
Autologous Transplantation
100%
Melphalan
100%
Maintenance Therapy
100%
Transplantation Therapy
100%
Lenalidomide
83%
Prednisone
83%
Lenalidomide Maintenance
83%
Confidence Interval
66%
Overall Survival
66%
Hazard Ratio
66%
Progression-free Survival
66%
High-dose Melphalan
66%
Stem Cell Transplantation
50%
Neutropenia
33%
Median Progression-free Survival
33%
Consolidation Therapy
33%
Toxic Effects
16%
Newly Diagnosed multiple Myeloma
16%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
16%
Phase II Study
16%
Body Surface Area
16%
Gastrointestinal Side Effects
16%
Medicine and Dentistry
Multiple Myeloma
100%
Autotransplantation
100%
Maintenance Therapy
100%
Lenalidomide
100%
Melphalan
100%
Progression Free Survival
60%
Prednisone
50%
Hazard Ratio
40%
Overall Survival
40%
Drug Megadose
40%
Stem Cell Therapy
30%
Neutropenia
20%
Adverse Event
10%
Infection
10%
Body Surface
10%
Dermatological Agent
10%
Autologous Stem Cell Transplantation
10%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
100%
Lenalidomide
100%
Melphalan
100%
Progression Free Survival
60%
Prednisone
50%
Overall Survival
40%
Neutropenia
20%
Infection
10%
Adverse Event
10%
Dermatological Agent
10%